Piper Sandler Assumes AbCellera Biologics at Overweight, Announces Price Target of $20
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Allison Bratzel has assumed coverage of AbCellera Biologics (NASDAQ:ABCL) with an Overweight rating and a price target of $20.
October 13, 2023 | 10:29 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler has assumed coverage of AbCellera Biologics with an Overweight rating and a price target of $20, which could positively impact the stock.
Analyst ratings and price targets can significantly influence a stock's performance. In this case, Piper Sandler's Overweight rating and $20 price target for AbCellera Biologics suggest a positive outlook for the stock, which could lead to an increase in its price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100